Med
March 8, 2024
Joshua D. Rosenblat, Shakila Meshkat, Zoe Doyle et al.
97 citations
Psilocybin-assisted psychotherapy (PAP) has been associated with antidepressant effects. Trials to date have typically excluded participants with complex presentations. Our aim was to determine the feasibility of PAP in a complex population, including high levels of treatment resistance in major depressive and bipolar disorder and patients with baseline suicidality and significant comorbidity....
International Journal of Mental Health and Addiction
March 7, 2024
Brandon Weiss, Leor Roseman, Bruna Giribaldi et al.
26 citations
Abstract The mechanisms by which Psilocybin Therapy (PT) improves depression remain an important object of study, with scientists actively exploring acute psychological experiences and neurobiological processes as candidates. In a phase 2, double-blind, randomized, active comparator controlled trial involving patients with moderate-to-severe major depressive disorder, we investigated whether...
Brain Sciences
March 3, 2024
Mario Renato Velit-Salazar, Eloise Cherian, Paulo R Shiroma
13 citations
Objective: This study aims to provide an overview of pharmacological trials that examine the neurocognitive effects of psychedelics among healthy individuals and patients with post-traumatic stress disorder (PTSD) or major depressive disorder (MDD). Methods: The Preferred Reporting Items for Systematic Reviews (PRISMA) was used as a guide to structure and report the findings for this review. A...
Psychedelic Medicine
March 1, 2024
Justin C Strickland, Albert Garcia‐romeu, Matthew W Johnson
20 citations
The Mystical Experience Questionnaire (MEQ-30) and Challenging Effects Questionnaire (CEQ) are two of the most widely used, validated instruments to probe subjective effects of psychedelic drugs. However, these assessments are lengthy and can be a burden to study participants or patients if administered during acute psychedelic effects, after resolution of psychedelic effects when participants...
Journal of Affective Disorders
February 27, 2024
Debora Copa, David Erritzøe, Bruna Giribaldi et al.
31 citations
BackgroundPsilocybin is a serotonergic psychedelic drug under assessment as a potential therapy for treatment-resistant and major depression. Heterogeneous treatment responses raise interest in predicting the outcome from baseline data.MethodsA machine learning pipeline was implemented to investigate baseline resting-state functional connectivity measured with functional magnetic resonance...
Frontiers in Psychiatry
February 15, 2024
Shuping Fang, Xin Yang, Wei Zhang
21 citations
Introduction Psilocybin is a classic psychedelics, which has been shown to have antidepressant effects by many studies in recent years. In this study, we aim to evaluate the efficacy, acceptability and tolerability of psilocybin in the treatment of primary (major depressive disorder) or secondary (experiencing distress related to life-threatening diagnoses and terminal illness) depression....
Scientific Reports
February 5, 2024
Alistair Niemeijer, Erwin Krediet, Jeanine Kamphuis et al.
50 citations
Abstract Psilocybin is the most researched classic psychedelic for Treatment-Resistant Depression (TRD). While optimizing set and setting are considered essential for efficacy and safety, patient perspectives on these aspects have rarely been investigated. To address this knowledge gap, the current paper explored the experiences of 11 TRD patients (8 women, 3 men) participating in a...
Science Translational Medicine
January 10, 2024
Katie Kamenish, Roberto Arban, Aslihan Selimbeyoglu et al.
26 citations
How rapid-acting antidepressants (RAADs), such as ketamine, induce immediate and sustained improvements in mood in patients with major depressive disorder (MDD) is poorly understood. A core feature of MDD is the prevalence of cognitive processing biases associated with negative affective states, and the alleviation of negative affective biases may be an index of response to drug treatment....
2024
Tessa Watford
Depression is a debilitating mental health condition affecting millions worldwide. While antidepressant medications are widely prescribed, they often come with significant side effects and limited efficacy. Tessa Watford, a researcher in the field of neuroscience, has conducted a systematic review exploring the therapeutic potential of psilocybin, a naturally occurring psychedelic compound, for...
Journal of the Netherlands Society of Toxicology
2024
Marcha Verheijen
1 citation
Depression, affecting over 264 million people globally, presents significant treatment challenges, often due to the limited efficacy and adverse effects of traditional antidepressants and the accessibility issues associated with psychotherapy. Recent advancements in psychedelic-assisted therapy, particularly using psilocybin, a naturally occurring compound found in “magic mushrooms”, shows...